Effect of Indomethacin on the Progression of Alzheimer's Disease
The purpose of this study is determine whether indomethacin is able to retard disease progression in patients with mild to moderate Alzheimer's disease.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Effect of Indomethacin on the Progression of Alzheimer's Disease|
- Score on the Cognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months.
- Score on the Noncognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months
- Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months
- Score on the Mini-Mental State Examination at 12 months
- Score on the Neuropsychiatric Inventory at 12 months
- Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months
- The occurrence of adverse events during 12 months of treatment
|Study Start Date:||May 2000|
|Estimated Study Completion Date:||August 2005|
Previous research indicates that inflammation plays a role in the pathogenesis of Alzheimer’s disease (AD), and nonsteroidal anti-inflammatory drugs (NSAIDs) may retard the progression of the disease.
Comparison(s): Cognitive decline of patients with mild to moderate AD receiving the NSAID indomethacin, compared to cognitive decline of patients with mild to moderate AD receiving placebo, during a one-year period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00432081
|Arnhem, Netherlands, 6800 TA|
|Radboud University Medical Center|
|Nijmegen, Netherlands, 6500 HB|
|Principal Investigator:||Rene WM Jansen, MD, PhD||Radboud University Medical Center Nijmegen|
|Principal Investigator:||Berry PH Kremer, MD, PhD||Radboud University Medical Center Nijmegen|
|Study Director:||Danielle De Jong, MD||Radboud University Medical Center Nijmegen|